替非珠單抗

替非珠單抗（INN：Tefibazumab）是一種人源化單克隆抗體，用於治療金黃色葡萄球菌的嚴重感染。可能的適應症包括治療患有囊性纖維化的2a期患者的金黃色葡萄球菌^[1]和耐甲氧西林金黃色葡萄球菌。^[2]該藥物由Inhibitex開發的。^[3]

參見[編輯]

^ Clinical trial number NCT00198289 for "Aurexis in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs" at ClinicalTrials.gov
^ Pan A, Lorenzotti S, Zoncada A. Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection. Recent Patents on Anti-Infective Drug Discovery. January 2008, 3 (1): 10–33. PMID 18221183. doi:10.2174/157489108783413173.
^ John JF. Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection. Current Opinion in Molecular Therapeutics. October 2006, 8 (5): 455–60. PMID 17078388.